Page 63 - Read Online

Wang et al. Genotoxic NF-kB activation in cancer

cancer cells was significantly attenuated by PARP-1 participants or animals.
inhibitors. [168] Moreover, a PARP1 inhibitor, AG-014699
was shown to sensitize glioma cells to radiation via REFERENCES
inhibiting NF-kB activation. [169] Thus, inhibiting PARP1
may not only further diminish the DNA repair capacity 1. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular
of BRCA-deficient breast cancer cells, but also abolish mechanisms of mammalian DNA repair and the DNA damage
genotoxic drug-induced NF-kB activation and sensitize checkpoints. Annu Rev Biochem 2004;73:39-85.
TNBC patients to chemotherapy. 2. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair
and the cancer connection. Nat Genet 2001;27:247-54.
3. De Bont R, van Larebeke N. Endogenous DNA damage in humans: a
CONCLUSION AND PERSPECTIVE review of quantitative data. Mutagenesis 2004;19:169-85.
4. Ciccia A, Elledge SJ. The DNA damage response: making it safe to
The studies on DNA damage response and NF-kB have play with knives. Mol Cell 2010;40:179-204.
significantly improved our understanding of molecular 5. d’Adda di Fagagna F. Living on a break: cellular senescence as a
signaling leading to genotoxic NF-kB activation DNA-damage response. Nat Rev Cancer 2008;8:512-22.
in the last two decades. These studies have also 6. McCool KW, Miyamoto S. DNA damage-dependent NF-kappa B
activation: NEMO turns nuclear signaling inside out. Immunol Rev
provided promising drug targets, such as PARP-1, for 2012;246:311-26.
selectively inhibiting NF-kB activation by radiation 7. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-
and chemotherapeutics in cancer cells, which may be binding protein Nf-kappa B by a posttranslational mechanism. Cell
able to resensitize treatment-refractory cancer cells to 1986;47:921-8.
conventional chemotherapy. The extension of the period 8. Sen R, Baltimore D. Multiple nuclear factors interact with the
that cancer patients can benefit from these cost-effective immunoglobulin enhancer sequences. Cell 1986. 46: 705-716. J
“old” chemotherapeutic drugs will also substantially 9. Immunol 2006;177:7485-96.
Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-
alleviate the financial burden the patients bear due to kappa B transcription factor. Science 1988;242:540-6.
the high cost of newly developed therapeutic agents. 10. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation.
Nevertheless, further investigation is still much needed Nat Rev Immunol 2008;8:837-48.
to explore the critical downstream NF-kB-target genes 11. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell
which are specifically induced by DNA damage. Better 2008;132:344-62.
understanding of how these induced genes, protein 12. Piret B, Piette J. Topoisomerase poisons activate the transcription
genes or non-coding RNAs, modulate cell response factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res
1996;24:4242-8.
to DNA damage, will help to develop novel therapeutic 13. Habraken Y, Piret B, Piette J. S phase dependence and involvement
agents selectively targeting those pro-survival/ of NF-kappaB activating kinase to NF-kappaB activation by
metastatic targets and counteract acquired therapeutic camptothecin. Biochem Pharmacol 2001;62:603-16.
resistance. Furthermore, these gene signatures may 14. Wu ZH, Miyamoto S. Many faces of NF-kappa B signaling induced
also serve as predictive biomarkers for evaluating the by genotoxic stress. J Mol Med (Berl) 2007;85:1187-202.
potential benefit and effectiveness in patients who 15. Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS,
receive cytotoxic chemotherapies and radiation. Voce DJ, Darga TE, Weichselbaum RR, Yamini B. p50 (NF-kappaB1)
is an effector protein in the cytotoxic response to DNA methylation
damage. Mol Cell 2011;44:785-96.
Authors’ contributions 16. Campbell KJ, Witty JM, Rocha S, Perkins ND. Cisplatin mimics ARF
The study’s conception and design: W. Wang, A.M. tumor suppressor regulation of RelA (p65) nuclear factor-kappaB
Mani, Z.H. Wu transactivation. Cancer Res 2006;66:929-35.
Paper’s writing: W. Wang, A.M. Mani, Z.H. Wu 17. Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in
Manuscripts review and edition: Z.H. Wu somatic mammalian cells. Biochem J 2009;423:157-68.
18. Goodarzi AA, Noon AT, Jeggo PA. The impact of heterochromatin on
DSB repair. Biochem Soc Trans 2009;37:569-76.
Financial support and sponsorship 19. Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA repair
The work in the authors’ laboratory has been supported in cancer: beyond PARP inhibitors. Cancer Discov 2017;7:20-37.
by NIH R01CA149251 and American Cancer Society 20. Vilenchik MM, Knudson AG. Endogenous DNA double-strand
(RSG-13-186-01-CSM). breaks: production, fidelity of repair, and induction of cancer. Proc
Natl Acad Sci U S A 2003;100:12871-6.
Conflicts of interest 21. Branzei D, Foiani M. Maintaining genome stability at the replication
There are no conflicts of interest. fork. Nat Rev Mol Cell Biol 2010;11:208-19.
22. Dillon LW, Burrow AA, Wang YH. DNA instability at chromosomal
Patient consent fragile sites in cancer. Curr Genomics 2010;11:326-37.
There is no patient involved. 23. Stracker TH, Theunissen JW, Morales M, Petrini JH. The Mre11
complex and the metabolism of chromosome breaks: the importance
of communicating and holding things together. DNA Repair (Amst)
Ethics approval 2004;3:845-54.
This article does not contain any studies with human 24. Lavin MF. ATM and the Mre11 complex combine to recognize and
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ March 27, 2017 55